AlzChem Group Balance Sheet Health
Financial Health criteria checks 6/6
AlzChem Group has a total shareholder equity of €182.6M and total debt of €53.6M, which brings its debt-to-equity ratio to 29.3%. Its total assets and total liabilities are €463.4M and €280.9M respectively. AlzChem Group's EBIT is €66.8M making its interest coverage ratio 26.4. It has cash and short-term investments of €46.1M.
Key information
29.3%
Debt to equity ratio
€53.55m
Debt
| Interest coverage ratio | 26.4x |
| Cash | €46.07m |
| Equity | €182.55m |
| Total liabilities | €280.87m |
| Total assets | €463.43m |
Recent financial health updates
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07
Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11Recent updates
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year
Aug 07Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Jul 20Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?
Jul 03Financial Position Analysis
Short Term Liabilities: ACT's short term assets (€255.9M) exceed its short term liabilities (€109.9M).
Long Term Liabilities: ACT's short term assets (€255.9M) exceed its long term liabilities (€170.9M).
Debt to Equity History and Analysis
Debt Level: ACT's net debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: ACT's debt to equity ratio has reduced from 150.7% to 29.3% over the past 5 years.
Debt Coverage: ACT's debt is well covered by operating cash flow (180.5%).
Interest Coverage: ACT's interest payments on its debt are well covered by EBIT (26.4x coverage).